Placenta cells tested as COVID fighter – but trial stopped early
NCT ID NCT04365101
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new therapy called CYNK-001, which uses natural killer cells from the placenta to fight COVID-19. It enrolled only 7 adults with moderate COVID-19. The study was terminated early, so we have limited information on safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CYNK-001 (natural killer cells from placenta)
- What this could lead to
- If successful, this could point toward a cell-based therapy to help the immune system fight COVID-19.
- What could go wrong
- This was a very early, small trial (only 7 people) that was terminated early, so results are limited. Cell therapies can have side effects like infusion reactions or immune system overactivation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANALGESICS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atlantic Health
Morristown, New Jersey, 07960, United States
-
Atlantic Health
Summit, New Jersey, 07901, United States
-
Multicare Health System
Tacoma, Washington, 98405, United States
-
UC Irvine
Irvine, California, 92697, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cutting radiation in CT scans: a new test of Ultra-Low-Dose imaging
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- AI could outsmart bacteria: a smarter way to choose antibiotics?